Vacirca Jeff L 4

What Happened Jeff L. Vacirca, a director of Caris Life Sciences, purchased 31,050 shares in open-market transactions on May 11, 2026. The weighted average price reported was $16.15 per share (range $16.13–$16.15), for a total reported acquisition value of $501,426. This was a purchase (P) — an acquisition rather than a sale.

Key Details

• Transaction date: 2026-05-11 (reported on Form 4 filed 2026-05-12).
• Price: weighted average $16.15; actual trade prices ranged from $16.13 to $16.15 (per footnote).
• Shares acquired: 31,050; aggregate cost: $501,426.
• Shares owned after transaction: not disclosed on the provided summary of the filing.
• Footnote: reporting person will provide breakdown of the number of shares purchased at each separate price within the $16.13–$16.15 range upon request.
• Timeliness: Filing was submitted the next day (appears timely; no late-filing indication).

Context This is a direct open-market purchase by a company director. Purchases by insiders can be viewed as informative to investors, but they are not proof of future company performance. No option exercises, gifts, or tax-withholding actions are reported in this transaction.